HR+/HER2− BC patients progressing on initial ET can switch ET while continuing CDK4/6iJune 16, 2023Breast Cancer
HR+/HER2− BC: Dalpiciclib plus letrozole or anastrozole shows promise in phase 3June 16, 2023Breast Cancer
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncologyJune 15, 2023Breast CancerMetastatic Breast Cancer
New study backs up capecitabine dosing practice in metastatic BCJune 14, 2023Metastatic Breast CancerBreast Cancer
In TNBC, repeated biopsies may reveal emergent HER2-low expressionJune 13, 2023Breast CancerMetastatic Breast Cancer
Ribociclib forestalls recurrence also in early breast cancerJune 4, 2023Breast CancerMetastatic Breast Cancer
How a medical recoding may limit cancer patients’ options for breast reconstructionJune 1, 2023Breast Cancer
Commentary: Trastuzumab, breast density, and extended treatment in BC, June 2023May 30, 2023Breast Cancer
